GHK-Cu, the "copper" peptide.
A copper-binding tripeptide first isolated from human plasma in 1973. Studies link it to collagen, elastin, and faster wound healing.
Promising? very. Most strong human data is topical, not injected.
peptides, clarified.
@agingdoc1 GLP-1s touching skin biology sounds weird until you remember these receptors aren’t locked inside the obesity aisle.
Interesting artcle. I’d still want the clean split between direct receptor effects and downstream weight/inflammation changes.
@RetaDiary This is the piece most GLP talk keeps missing. The drug can lower friction, but it doesn’t design the day for you. The win is when appetite noise drops enough that gym, walking, sleep, and food prep can actually stick.!
@fitcapbiohacker Reta being “easy mode” is exactly why the long-term question matters.
Amazing tool if it gives people back control, but “never stop” is a big claim for a class where durability, side effects, and maintenance strategy still largely unknown
@NatureMedicine The liver-fat signal is the part that makes GLP-1/glucagon dual agonism more interesting than another weight-loss headline.
Weight moves the conversation. Organ fat and MASLD endpoints are where it starts to get clinically serious.
@peptidecatalog The glucagon piece is the part people keep under-explaining.
Semaglutide, tirzepatide, and reta are not just “stronger versions” of the same thing. The receptor mix changes what problem each drug is trying to solve.
@midjourney Unreal. How lucky are we to live in a time where things like this exists and many other advancements that are coming online to manage and take our health into our own hands? Kudos @midjourney !!!
@NovaLabs_62 "Start with a goal, not a peptide" is the line most people skip.
Half the bad stack design online is people collecting compounds before they know what they're trying to achieve
Peptides do not need more hype.
They need translation.
The research is dense.
The community language is messy.
The marketing is often reckless.
The buyer is left stitching it together alone.
Curo is being built around a simple premise:
sourcing is table stakes.
Understanding is the work.
The gray-market peptide space taught people how to shop.
It did not teach them how to think.
Price.
Milligrams.
COA.
Discount code.
Checkout.
That is not enough.
The real advantage is knowing what a compound is being studied for, what the research can support, and where the story turns speculative.
That is the product layer most brands skipped.
“Research use only” became a hiding place.
It should have been a standard.
A serious peptide brand should not use that phrase to dodge clarity.
It should use it to set the frame:
educational
evidence-aware
mechanism-first
no miracle language
no pretending animal data is human proof
That is the line Curo is drawing.
Most peptide brands make the same bet:
“Trust us.”
Curo is making a different one:
“Understand it.”
What is it?
Why do researchers care?
Where is the evidence strong?
Where is it thin?
What are people exaggerating?
The future of this category is not louder claims.
It is better context.
The peptide market does not have a sourcing problem.
It has an understanding problem.
Anyone can put “third-party tested” on a product page.
Very few can explain what the compound is, what the research actually shows, what is still uncertain, and why the hype got ahead of the evidence.
That is the gap Curo is built for.
Peptides, clarified.
@DailyPeptide@idrozd Been researching and exploring crowdfunding peptides that pharma won't touch... I agree that the current situation would be a hard hill to climb, but as these become more mainstream, I can see this changing over the next few years 🤞